| Literature DB >> 27805919 |
Molly P Hogan1, Joseph Osborne, Gary A Ulaner.
Abstract
Intrathecal methotrexate is a standard option for central nervous system-directed therapy in patients with stage III and IV diffuse large B-cell lymphoma. We present a case of a 50-year-old man with stage IV diffuse large B-cell lymphoma with widespread lymphomatous involvement including the central nervous system, who received 7 doses of intrathecal methotrexate via Ommaya catheter. Posttherapy F-FDG-PET/CT imaging demonstrated diffuse, intense intrathecal FDG avidity, without correlative findings on MR spinal imaging. FDG avidity resolved on follow-up. These PET/CT findings are most consistent with methotrexate-induced thecal inflammation, which needs to be distinguished from intrathecal malignancy.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27805919 PMCID: PMC5583704 DOI: 10.1097/RLU.0000000000001440
Source DB: PubMed Journal: Clin Nucl Med ISSN: 0363-9762 Impact factor: 7.794